J-ALEX: control of CNS disease
Kim, et al. WCLC 2016 (Abs. MA07.03)
Time to progression of CNS disease in
patients
with
CNS mets at baseline
Time (months)
Progression-free rate (%)
80
60
40
20
0
100
0
27
24
21
18
15
12
6
9
3
1
HR=0.16 (0.02–1.28)
p=0.0492
Alectinib (n=14; 7.1% with event)
Crizotinib (n=29; 34.5% with event)
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
